Dr. David Mathieu
Claim this profileCentre Hospitalier Universitaire de Sherbrooke
Studies Lung Cancer
Studies Brain Metastases
3 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials David Mathieu is currently running
Stereotactic Radiosurgery
for Brain Aneurysm
The goal of this clinical trial is to confirm the feasibility and safety of performing radiosurgery on unruptured, low-risk aneurysms in humans. Participants will choose if they want to undergo radiosurgery or not. Participants who choose not to have radiosurgery will be assigned to the observational group. Participants who choose to have radiosurgery performed will be assigned to the radiosurgery group. Participants in both groups will attend an initial exam session as well as four follow-up sessions: Day 0 * Initial questionnaire * CTA scan * MRI * Radiosurgery performed on patients in the radiosurgery group 6 months * CTA scan * Follow-up questionnaire 12 months * CTA scan * MRI * Follow-up questionnaire 24 months * CTA scan * Follow-up questionnaire 36 months * CTA scan * MRI * Follow-up questionnaire Researchers will compare the observational group and the radiosurgery group to see if there is a difference in the incidence of aneurysm rupture during the study period (3 years). The hypothesis is that radiosurgery should not increase the risk of aneurysm rupture.
Recruiting1 award N/A2 criteria
Tranexamic Acid
for Subdural Hematoma
BACKGROUND Chronic subdural hematoma (CSDH) is one of the most frequent reasons for cranial neurosurgical consult. There is no widely accepted medical treatment for CSDH. This trial will investigate whether Tranexamic Acid (TXA) can increase the rate of CSDH resolution following conservative management, lower the number of required surgical procedures and decrease the rate of CSDH recurrence following surgical evacuation. TRACS is a double blind, randomized, parallel-design, placebo-controlled, phase IIB study designed to provide preliminary efficacy data as well as feasibility, safety and incidence data required to plan a larger definitive phase III trial. METHODS Consecutive patients presenting at the Centre Hospitalier Universitaire de Sherbrooke with a recent (\< 14 days) diagnosis of subdural hematoma with a chronic component will be screened for eligibility. Exclusion criteria include specific risk factors for thromboembolic disease, anticoagulant use or contraindication to TXA. A total of 130 patients will be randomized to receive either 750 mg of TXA daily or placebo until complete radiological resolution of the CSDH or for a maximum of 20 weeks. CSDH volume will be measured on serial CT scanning. Cognitive function tests, quality of life questionnaires as well as functional autonomy assessments will be performed at enrollment, 10 weeks follow-up and 3 months post-treatment follow-up. During the treatment period, patients will undergo standard CSDH management with surgery being performed at the discretion of the treating physician. If surgery is performed, the CSDH and its outer membrane will be sampled for in vitro analysis. The primary outcome is the rate of CSDH resolution at 20 weeks without intervening unplanned surgical procedure. Secondary outcomes include CSDH volume, incidence of surgical evacuation procedures, CSDH recurrence, cognitive functions, functional autonomy, quality of life, incidence of complications and length of hospital stay. Planned subgroup analyses will be performed for conservatively vs surgically-managed subjects and highly vs poorly vascularised CSDH. DISCUSSION CSDH is a frequent and morbid condition for which an effective medical treatment has yet to be discovered. The TRACS trial will be the first prospective study of TXA for CSDH.
Recruiting0 awards Phase 2 & 32 criteria
More about David Mathieu
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments David Mathieu has experience with
- NovoTTF-100M Device
- NovoTTF-200M Device
- Stereotactic RadioSurgery (SRS)
- Tranexamic Acid
- Placebo
Breakdown of trials David Mathieu has run
Lung Cancer
Brain Metastases
Non-Small Cell Lung Cancer
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Mathieu specialize in?
David Mathieu focuses on Lung Cancer and Brain Metastases. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is David Mathieu currently recruiting for clinical trials?
Yes, David Mathieu is currently recruiting for 2 clinical trials in Sherbrooke Quebec. If you're interested in participating, you should apply.
Are there any treatments that David Mathieu has studied deeply?
Yes, David Mathieu has studied treatments such as NovoTTF-100M device, NovoTTF-200M device, Stereotactic RadioSurgery (SRS).
What is the best way to schedule an appointment with David Mathieu?
Apply for one of the trials that David Mathieu is conducting.
What is the office address of David Mathieu?
The office of David Mathieu is located at: Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec J1H 5N4 Canada. This is the address for their practice at the Centre Hospitalier Universitaire de Sherbrooke.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.